We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Predicts Response to Immunotherapy in Metastatic NSCLC

By LabMedica International staff writers
Posted on 10 Mar 2020
Print article
Image: Immunohistological micrograph showing a programmed death-ligand 1 (PD-L1) positive non-small cell lung carcinoma (Photo courtesy of Creative Commons BY-SA 4.0/Wikimedia).
Image: Immunohistological micrograph showing a programmed death-ligand 1 (PD-L1) positive non-small cell lung carcinoma (Photo courtesy of Creative Commons BY-SA 4.0/Wikimedia).
Non-small cell lung cancer (NSCLC) patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower measure of mutations.

NSCLC is the most common form of lung cancer, accounting for about 84% of all lung cancer cases. In patients with metastatic disease the five-year survival rate is just 6%. Immunotherapy with a PD-1 inhibitor, either alone or in combination with chemotherapy, is the standard first-line treatment in these cases when cancers do not have a targetable mutation.

Oncologists at the University of Pennsylvania (Philadelphia, PA, USA) and their colleagues enrolled 66 patients with newly diagnosed metastatic non-small cell lung cancer (mNSCLC) starting first-line pembrolizumab-based therapy, either alone or in combination with chemotherapy. Response was assessed using response evaluation criteria in solid tumors (RECIST 1.1.) rules. Associations were made for patient characteristics, 6-month durable clinical benefit (DCB), progression free survival (PFS), and overall survival (OS).

With a simple blood draw, the scientists can screen for mutations in 500 different genes. They used this liquid biopsy panel to measure the tumor mutational burden (TMB), essentially the number of mutations detectable in the blood of the enrolled patients, 52 of whom were evaluable for the trial. TMB is typically reported as mutations per megabase (Mb), which is the number non-synonymous, somatic mutations divided by the size of the genome coding area. The median TMB was 16.8 mutations per Mb and was significantly higher for patients who experienced a durable clinical benefit (DCB) compared to those who did not. A DCB means a patient experienced a complete response, a partial response, or stable disease for more than six months. Patients who achieved a DCB had a median of 21.3 mutations per Mb, compared to 12.4 in patients who did not achieve a DCB.

The team then examined the progression-free survival (PFS) and overall survival (OS) of both groups. The 28 patients with more than 16 detectable mutations per Mb had a median PFS of 14.1 months compared to 4.7 months for the 24 patients in the lower TMB group. Median OS was not reached for the high TMB group. The low TMB group had a median OS of 8.8 months.

Erica L. Carpenter, MBA, PhD, an assistant professor and senior author of the study, said, “We believe this is the largest study to show correlation between blood-based tumor mutational burden and clinical outcomes after first-line PD-1-based treatment, including combination chemo-immunotherapy, for NSCLC.”

The authors concluded that pTMB greater than or equal to 16 mutations/Mb is associated with improved PFS after first-line standard of care pembrolizumab-based therapy in mNSCLC. STK11/KEAP1/PTEN and ERBB2 mutations may help identify pTMB-high patients unlikely to respond. The study was published on February 26, 2020 in the journal Clinical Cancer Research.

Related Links:
University of Pennsylvania

Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Automated Blood Typing System
IH-500 NEXT
New
Automated Cell Counter
QuadCount
New
Silver Member
Static Concentrator
BJP 10

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Small molecule modulation of protein corona significantly enhances deep plasma proteome profiling (Photo courtesy of Mahmoudi Group)

Smarter Blood Tests Deliver Faster Diagnoses and Improved Outcomes

It has long been established that the earlier a disease is detected, the better the chances for a positive patient outcome. A novel method now offers an in-depth analysis of proteins in plasma, uncovering... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.